PET and MRI Reveal Early Evidence of Neurodegeneration in Spinocerebellar Ataxia Type 17
Open Access
- 31 May 2012
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 53 (7), 1074-1080
- https://doi.org/10.2967/jnumed.111.101543
Abstract
Spinocerebellar ataxia type 17 (SCA17) is a rare autosomal dominantly inherited neurodegenerative disorder presenting with a variable phenotype including ataxia, dystonia, chorea, and parkinsonism, as well as cognitive impairment. We evaluated morphologic and functional imaging characteristics to elucidate evidence of neurodegeneration in SCA17, even in the presymptomatic stage of the disease. Methods: Nine individuals of 3 large SCA17 pedigrees, including 4 presymptomatic mutation carriers, underwent cranial 3-dimensional MRI volumetry, as well as multitracer PET with 18F-FDG, 11C-d-threo-methylphenidate, and 11C-raclopride. Healthy subjects showing no signs of a neurologic or psychiatric disease served as controls. Results: MRI volumetry revealed atrophy of the cerebellum and caudate nucleus in manifesting patients (P = 0.04 and 0.05, respectively) and in presymptomatic mutation carriers (P = 0.04 and 0.01, respectively). PET demonstrated decreased glucose metabolism in the striatum, as well as in the cuneus, cingulum, and parietal lobe, in all SCA17 patients and presymptomatic mutation carriers. In addition, PET was closely correlated with motor performance as assessed by the Scale for the Assessment and Rating of Ataxia (P = 0.037) and Unified Parkinson Disease Rating Scale (P = 0.05) and with cognitive function as assessed by the Mini-Mental Status Examination (P = 0.037). Furthermore, 11C-raclopride PET showed impairment of the postsynaptic dopaminergic compartment of the putamen and caudate nucleus not only in manifest SCA17 patients (P = 0.04 and 0.008, respectively) but also in yet-unaffected mutation carriers (P = 0.05 and 0.05, respectively). The degree of postsynaptic dopaminergic dysfunction was associated with impairment of motor performance. In contrast, significant presynaptic dopaminergic deficits assessed with 11C-d-threo-methylphenidate PET were not detected. Conclusion: MRI volumetry, as well as 11C-raclopride and 18F-FDG PET, reveal neuronal dysfunction and neurodegeneration even in the presymptomatic stage and may serve as markers for disease activity in upcoming interventional trials on SCA17.Keywords
This publication has 36 references indexed in Scilit:
- Spinocerebellar ataxia type 17 associated with an expansion of 42 glutamine residues in TATA-box binding protein geneJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Spinocerebellar ataxia type 17 (SCA17): Oculomotor phenotype and clinical characterization of 15 Italian patientsZeitschrift für Neurologie, 2007
- Morphological basis for the spectrum of clinical deficits in spinocerebellar ataxia 17 (SCA17)Brain, 2006
- Behavioral Disorder, Dementia, Ataxia, and Rigidity in a Large Family With TATA Box-Binding Protein MutationArchives of Neurology, 2004
- Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17)Annals of Neurology, 2003
- Mutation at the SCA17 locus is not a common cause of parkinsonismParkinsonism & Related Disorders, 2003
- Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genesBrain, 2003
- Phenotypical variability of expanded alleles in the TATA-binding protein geneZeitschrift für Neurologie, 2003
- CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia.Brain, 2001
- SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding proteinHuman Molecular Genetics, 2001